A targeted glycoproteomic approach identifies cadherin-5 as a novel biomarker of metastatic breast cancer

Highlights ► HPA binding breast cancer serum proteins underwent proteomic identification. ► Pregnancy zone protein, polymeric immunoglobulin receptor and cadherin-5 emerged as potential markers of metastatic breast cancer. ► Proteomic analysis was verified by ELISAs. The cadherin-5 ELISA discriminat...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2013-01, Vol.328 (2), p.335-344
Main Authors: Fry, Simon A, Sinclair, John, Timms, John F, Leathem, Anthony J, Dwek, Miriam V
Format: Article
Language:English
Subjects:
Adult
Aged
agglutinins
Antigens
Antigens, CD - blood
Antigens, CD - metabolism
Biomarker
Biomarkers
Biomarkers, Tumor - blood
Biomedical research
blood serum
Breast cancer
breast neoplasms
Breast Neoplasms - blood
Breast Neoplasms - pathology
Cadherins - blood
Cadherins - metabolism
Chromatography
Female
glycoproteins
Glycoproteins - blood
Glycoproteins - metabolism
Glycosylation
Helix pomatia
Hematology, Oncology and Palliative Medicine
Humans
immunoglobulins
Lectins
Lectins - metabolism
Mass spectrometry
Metastasis
Middle Aged
Mortality
Neoplasm Grading
Neoplasm Metastasis
patients
Polypeptides
polysaccharides
pregnancy
Protein Binding
Proteins
Proteome
proteomics
Proteomics - methods
Reproducibility of Results
Sensitivity and Specificity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights ► HPA binding breast cancer serum proteins underwent proteomic identification. ► Pregnancy zone protein, polymeric immunoglobulin receptor and cadherin-5 emerged as potential markers of metastatic breast cancer. ► Proteomic analysis was verified by ELISAs. The cadherin-5 ELISA discriminated recurrent breast cancers from those with no sign of recurrence. ► Analysis of cadherin-5 glycosylation also showed a significantdifference between the two sample groups. ► Serum cadherin-5 discriminated patients with recurrent breast cancerfrom those with no sign of recurrence with 90% specificity.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2012.10.011